Skip to content
Shree Ganesh Remedies logo

Shree Ganesh Remedies

SGRL NSE
₹669.50 up 11.50 (1.75%)
Market Cap
₹859 Cr
P/E
55.70

Shree Ganesh Remedies (SGRL) share price was ₹658.00 at the 28 Oct 2026 close; market capitalisation ₹845 Cr; P/E (TTM) 54.74; sector Healthcare. The share price rose 34.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 41.8% year on year to ₹14.36 Cr and net profit fell 67.5% year on year to ₹1.12 Cr (compared with Jun 2025). Promoters held 72.84% of Shree Ganesh Remedies in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 54/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹658.00 +165.05 +33.48% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹859 Cr
P/E (TTM)
55.7
EBITDA
₹38.00 Cr
Return on Equity
10.9%
Debt to Equity
0.19
Book Value
₹126.95
EPS (TTM)
₹12.02
52W High
₹759.00
52W Low
₹381.10

Price-based figures as of 29 Oct 2026, 10:57 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.1035.034,23,747 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,626.0087.372,55,540 Cr15.250.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,595.7072.151,74,806 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,183.70107.891,17,988 Cr22.260.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.4026.271,17,745 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.7034.721,11,906 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.7032.841,10,733 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Shree Ganesh Remedies (this company)
₹669.5055.70859 Cr5.270.08%10.90%14.83%102 Cr15 Cr
Median 8 companies₹1,568.4045.371,17,867 Cr5.170.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

54 Average
Overall score

Data confidence 100/100

Category scores

Quality Strong 74
Returns, margins, earnings quality 22% weight
Valuation Poor 32
Cheap vs sector & own history 24% weight
Growth Poor 3
Sales & profit trajectory 9% weight
Financial Health Strong 69
Solvency, leverage, coverage 9% weight
Momentum Good 60
Trend strength, vol-adjusted 12% weight
Ownership Good 64
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 80.8 to 109 days.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

Neutral

Bearish
6
Neutral
7
Bullish
6

Moving Averages

Bullish

Bearish
4
Neutral
0
Bullish
6

Growth Rate

Revenue Growth
0% lower than 3Y

change over 1 year

Net Income Growth
-22.94% lower than 3Y

change over 1 year

Cash Flow Change
-22.57%

change over 1 year

EBITDA Margin Change
-11.38%

change over 1 year Operating margin 23.33% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
26.72
33.42
27.97
37.33
24.78
32.33
27.05
24.43
24.67
30.32
21.11
33.2
14.36
Expenses
20.16
24.19
19.76
20.39
16.65
21.02
17.14
14.55
17.37
20.7
14.38
21.82
11.01
Operating Profit
6.56
9.23
8.21
16.94
8.13
11.31
9.91
9.88
7.3
9.62
6.73
11.38
3.35
OPM %
24.55%
27.62%
29.35%
45.38%
32.81%
34.98%
36.64%
40.44%
29.59%
31.73%
31.88%
34.28%
23.33%
Other Income
0.73
0.8
1.11
1.32
0.54
0.19
0.71
2.29
0.66
0.69
0.66
1.02
0.94
Interest
0.01
0.01
0.02
0.15
0.32
0.43
0.38
0.96
0.94
1.01
0.74
0.88
0.32
Depreciation
1.02
1.41
1.88
1.86
2.02
2.42
2.7
2.42
2.42
2.59
2.67
2.8
2.44
PBT
6.26
8.61
7.42
16.25
6.33
8.65
7.54
8.79
4.6
6.71
3.98
8.72
1.53
Tax %
27.64%
23.81%
35.31%
22.46%
26.7%
25.78%
27.85%
24.8%
25%
26.23%
22.36%
28.1%
27.45%
Net Profit
4.54
6.55
4.8
12.59
4.65
6.42
5.43
6.6
3.45
4.96
3.1
6.27
1.12
EPS (₹)
3.55
5.12
3.75
9.84
3.62
5
4.23
5.14
2.69
3.86
2.41
4.88
0.87
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
16
16
20
27
35
58
49
71
91
126
109
109
99
Expenses
14
14
16
22
26
47
35
53
68
84
69
74
68
Operating Profit
2
2
4
5
9
11
14
18
23
42
39
35
31
OPM %
13%
12%
21%
19%
25%
19%
28%
25%
26%
33%
36%
32%
31%
Other Income
0
0
0
2
1
4
2
4
1
3
4
3
3
Interest
0
0
0
0
0
0
0
0
0
1
2
4
3
Depreciation
1
1
1
1
1
2
3
3
4
6
10
10
10
PBT
2
2
4
6
9
13
13
18
20
38
31
24
21
Tax %
33%
34%
33%
28%
28%
24%
25%
26%
25%
26%
26%
26%
—
Net Profit
1
1
3
5
6
10
10
13
15
28
23
18
15
EPS (₹)
7.94
6.75
16.5
3.66
4.88
7.52
7.62
10.47
11.86
21.97
18
13.84
12.02
Div. Payout %
0%
0%
0%
19%
18%
14%
18%
4%
2%
2%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
9
9
9
10
12
13
13
13
13
Reserves
12
13
15
20
25
33
40
50
75
109
132
150
Borrowings
0
0
0
2
1
2
0
0
33
36
38
31
Other Liabilities
2
2
5
5
7
8
10
15
18
12
8
14
Total Liabilities
15
16
21
36
41
52
61
77
138
171
192
208
Fixed Assets
4
4
4
6
14
16
19
27
58
81
95
105
CWIP
0
0
0
0
0
0
2
3
15
17
9
13
Investments
0
0
0
4
4
7
3
0
0
5
18
13
Other Assets
11
11
17
25
23
29
37
47
64
69
70
78
Total Assets
15
16
21
36
41
52
61
77
138
171
192
208
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-1
-2
2
-1
-5
4
3
13
17
30
31
24
Investing
1
1
0
-3
0
-3
-1
-12
-51
-33
-35
-9
Financing
0
0
0
8
0
0
-1
-1
39
10
-1
-12
Net Cash Flow
-1
0
2
4
-5
1
2
0
5
7
-6
3
Free Cash Flow
-1
-2
2
0
-5
4
3
-2
-32
-1
7
7
CFO/OP
-58
-79
44
-18
-60
35
24
75
73
92
104
81
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
93
133
136
78
101
104
99
94
112
59
75
109
Inventory Days
132
130
103
102
125
56
206
132
138
156
223
209
Days Payable
43
32
90
43
75
39
101
92
118
51
61
82
Cash Conversion Cycle
183
232
149
137
151
120
205
134
133
164
238
236
Working Capital Days
160
202
172
128
145
102
158
133
122
89
111
128
ROCE %
16%
12%
26%
27%
27%
33%
28%
33%
22%
28%
19%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Shree Ganesh Remedies insights

64 extracted metrics + investor summaries across FY15–FY27.

Shareholding Pattern

DIIs0.99%Promot.72.84%Others2.10%Public24.07%As ofSep 2026

Documents

Frequently Asked Questions about Shree Ganesh Remedies

What does Shree Ganesh Remedies Ltd do?
Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.[1] [2]
Where is Shree Ganesh Remedies Ltd (SGRL) listed?
Shree Ganesh Remedies Ltd trades as SGRL on the NSE and under code 540737 on the BSE.
Which sector does Shree Ganesh Remedies Ltd belong to?
Shree Ganesh Remedies Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Shree Ganesh Remedies Ltd?
Shree Ganesh Remedies Ltd has a market capitalisation of ₹859.3 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Shree Ganesh Remedies Ltd?
Shree Ganesh Remedies Ltd trades at a PE ratio of 55.70 as of 29 Oct 2026, on earnings per share of ₹12.02, against a book value of ₹126.95 per share.
What is the 52-week high and low of Shree Ganesh Remedies Ltd?
Over the last 52 weeks Shree Ganesh Remedies Ltd has traded between ₹381.1 and ₹759 as of 29 Oct 2026.
Does Shree Ganesh Remedies Ltd pay dividends?
Shree Ganesh Remedies Ltd has a dividend yield of 0.08%.
What is the Return on Equity (ROE) of Shree Ganesh Remedies Ltd?
Shree Ganesh Remedies Ltd reported a return on equity of 10.90%. Its debt-to-equity ratio is 0.19.

Company Information

Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.[1] [2]

Website ganeshremedies.com
Listed 2017-10-13
Face Value ₹ 10
Shares Outstanding 1,28,34,922

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540737.md for Shree Ganesh Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month